文献速递脑血管病外科神经重症

入院纤维蛋白原降低预测低级别动脉瘤性蛛网膜下腔出血6个月死亡率

Reduced Admission Serum Fibrinogen Levels Predict 6-Month Mortality of Poor-Grade Aneurysmal Subarachnoid Hemorrhage.
PubMed 文献 · World Neurosurg · 2019-08-30

该回顾性研究纳入66例2010至2015年接受神经外科夹闭术的低级别动脉瘤性蛛网膜下腔出血患者,入院即刻采血检测纤维蛋白原。多因素分析显示Hunt-Hess V级和入院纤维蛋白原<2.5 g/L与6个月死亡率独立相关,纤维蛋白原降低亦与迟发性脑缺血相关。

要点

  • 入院纤维蛋白原<2.5 g/L与低级别aSAH患者6个月死亡风险升高独立相关。
  • Hunt-Hess V级同样与6个月死亡率独立相关,OR为3.89。
  • 入院纤维蛋白原水平与迟发性脑缺血呈负相关,低水平者风险更高。

核心结论

  • 低级别aSAH患者入院纤维蛋白原降低与迟发性脑缺血和6个月死亡率升高相关。
  • 入院血清纤维蛋白原水平可能作为接受手术的低级别aSAH患者的预测指标和治疗靶点。

研究设计与样本

  • 入院即刻采集血清样本,记录基线信息、并发症和6个月结局。
  • 采用单因素和多因素logistic回归分析纤维蛋白原水平与临床结局的关系。

主要发现

  • 66例患者中18例在初始出血后6个月内死亡,48例存活。
  • 多因素分析显示Hunt-Hess V级与6个月死亡率显著相关(OR 3.89,95%CI 1.06-14.20,P=0.04)。
  • 入院血清纤维蛋白原<2.5 g/L与6个月死亡率显著相关(OR 6.15,95%CI 1.67-22.67,P=0.006)。
  • 入院血清纤维蛋白原<2.5 g/L与迟发性脑缺血显著相关(OR 3.86,95%CI 0.99-15.09,P=0.05)。

关键数值与推荐

  • 入院血清纤维蛋白原<2.5 g/L作为预测6个月死亡率的界值(OR 6.15,95%CI 1.67-22.67,P=0.006)。
  • 入院血清纤维蛋白原<2.5 g/L与迟发性脑缺血相关(OR 3.86,95%CI 0.99-15.09,P=0.05)。

临床怎么用

  • 对接受手术的低级别aSAH患者,入院时可检测血清纤维蛋白原水平以辅助风险评估。
  • 纤维蛋白原降低的患者可能需加强迟发性脑缺血监测和围手术期管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To retrospectively analyze the relationship between fibrinogen levels and outcomes in poor-grade aneurysmal subarachnoid hemorrhage (aSAH). METHODS: We recruited 66 patients with poor-grade aSAH who were treated by neurosurgical clipping between January 2010 and December 2015. Serum samples were taken immediately on admission. Baseline information, complications, and outcomes at 6 months were recorded. Univariate and multivariate logistic regression analyses were used to explore the relationship between fibrinogen levels and clinical outcomes. RESULTS: Nineteen men and 47 women were included; the average age was 57.2 years. The median of the admission serum fibrinogen level was 3.3 g/L. Of the 66 patients, 18 had died by 6 months after initial hemorrhage, whereas 48 patients survived. Multivariate analyses showed that Hunt and Hess grade V (odds ratio [OR], 3.89; 95% confidence interval [CI], 1.06-14.20; P = 0.04) and admission serum fibrinogen level <2.5 g/L (OR, 6.15; 95% CI, 1.67-22.67; P = 0.006) were significantly associated with 6-month mortality. In addition, admission serum fibrinogen level was negatively correlated with delayed cerebral ischemia, and admission serum fibrinogen level <2.5 g/L (OR, 3.86; 95% CI, 0.99-15.09; P = 0.05) was also significantly associated with delayed cerebral ischemia. CONCLUSIONS: Patients with poor-grade aSAH with reduced admission fibrinogen level have a higher risk of delayed cerebral ischemia and 6-month mortality compared with those without. The admission serum fibrinogen level might be useful as a predictor and treatment target in patients with poor-grade sSAH who have undergone surgical treatment.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Xie B, Lin Y, Wu X, et al. Reduced Admission Serum Fibrinogen Levels Predict 6-Month Mortality of Poor-Grade Aneurysmal Subarachnoid Hemorrhage. World Neurosurg. 2019. PMID: 31476464. doi:10.1016/j.wneu.2019.08.155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。